Literature DB >> 21273402

Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Véronique M André1, Carlos Cepeda, Yvette E Fisher, My Huynh, Nora Bardakjian, Sumedha Singh, X William Yang, Michael S Levine.   

Abstract

There is considerable evidence that alterations in striatal medium-sized spiny neurons (MSSNs) giving rise to the direct (D1 receptor-expressing) and indirect (D2 receptor-expressing) pathways differentially contribute to the phenotype of Huntington's disease (HD). To determine how each subpopulation of MSSN is functionally affected, we examined spontaneous excitatory postsynaptic currents (sEPSCs) and dopamine (DA) modulation in two HD mouse models, the YAC128 and the BACHD (a bacterial-artificial chromosome). These mice also expressed enhanced green fluorescent protein (EGFP) under the control of the promoter for either DA D1 or D2 receptors to identify neurons. In early symptomatic YAC128 and BACHD mice, glutamate transmission was increased in both D1 and D2 MSSNs, but in different ways. D1 cells displayed increased sEPSC frequencies and decreased paired-pulse ratios (PPRs) while D2 cells displayed larger evoked glutamate currents but no change in sEPSC frequencies or PPRs. D1 receptor modulation of sEPSCs was absent in D1-YAC128 cells at the early symptomatic stage but was restored by treating the slices with tetrabenazine. In contrast, in fully symptomatic YAC128 mice, glutamate transmission was decreased specifically in D1 cells, and D1 receptor modulation was normal in D1-YAC128 cells. Behaviorally, early symptomatic mice showed increased stereotypies that were decreased by tetrabenazine treatment. Together, these studies support differential imbalances in glutamate and DA transmission in direct and indirect pathway MSSNs. Stereotypic behavior at an early stage could be explained by increased glutamate activity and DA tone in direct pathway neurons, whereas hypokinesia at later stages could result from reduced input onto these neurons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273402      PMCID: PMC3071260          DOI: 10.1523/JNEUROSCI.3539-10.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  56 in total

Review 1.  The neostriatal mosaic: multiple levels of compartmental organization.

Authors:  C R Gerfen
Journal:  Trends Neurosci       Date:  1992-04       Impact factor: 13.837

Review 2.  Short-term synaptic plasticity.

Authors:  R S Zucker
Journal:  Annu Rev Neurosci       Date:  1989       Impact factor: 12.449

Review 3.  Disinhibition as a basic process in the expression of striatal functions.

Authors:  G Chevalier; J M Deniau
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

4.  Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease.

Authors:  G A Graveland; R S Williams; M DiFiglia
Journal:  Science       Date:  1985-02-15       Impact factor: 47.728

5.  Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.

Authors:  R L Albin; A Reiner; K D Anderson; L S Dure; B Handelin; R Balfour; W O Whetsell; J B Penney; A B Young
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

6.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

7.  Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.

Authors:  D Sulzer; N T Maidment; S Rayport
Journal:  J Neurochem       Date:  1993-02       Impact factor: 5.372

8.  Differential loss of striatal projection neurons in Huntington disease.

Authors:  A Reiner; R L Albin; K D Anderson; C J D'Amato; J B Penney; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  The quinolinic acid model of Huntington's disease: locomotor abnormalities.

Authors:  P R Sanberg; S F Calderon; M Giordano; J M Tew; A B Norman
Journal:  Exp Neurol       Date:  1989-07       Impact factor: 5.330

10.  Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry.

Authors:  R J Ferrante; N W Kowall; E P Richardson
Journal:  J Neurosci       Date:  1991-12       Impact factor: 6.167

View more
  75 in total

1.  Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.

Authors:  Mark F Mehler; Jenna R Petronglo; Eduardo E Arteaga-Bracho; Maria E Gulinello; Michael L Winchester; Nandini Pichamoorthy; Stephen K Young; Christopher D DeJesus; Hifza Ishtiaq; Solen Gokhan; Aldrin E Molero
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

2.  Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Authors:  Sandra M Holley; Laurie Galvan; Talia Kamdjou; Carlos Cepeda; Michael S Levine
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

3.  Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.

Authors:  Dohee Kim; Jeha Jeon; Eunji Cheong; Dong Jin Kim; Hoon Ryu; Hyemyung Seo; Yun Kyung Kim
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

4.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

5.  Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease.

Authors:  Joshua L Plotkin; Michelle Day; Jayms D Peterson; Zhong Xie; Geraldine J Kress; Igor Rafalovich; Jyothisri Kondapalli; Tracy S Gertler; Marc Flajolet; Paul Greengard; Mihaela Stavarache; Michael G Kaplitt; Jim Rosinski; C Savio Chan; D James Surmeier
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

Review 6.  Direct and indirect pathways of basal ganglia: a critical reappraisal.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Veronica Ghiglieri; Massimiliano Di Filippo
Journal:  Nat Neurosci       Date:  2014-07-28       Impact factor: 24.884

Review 7.  Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Authors:  Laurie Galvan; Véronique M André; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  J Huntingtons Dis       Date:  2012

8.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

9.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

Review 10.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.